medigraphic.com

2015, Número 2

<< Anterior Siguiente >>

Rev Clin Esc Med 2015; 5 (2)


Micro ARN y Enfermedad pulmonar obstructiva crónica

Monge ZAC, Estrada GCF

Idioma: Español
Referencias bibliográficas: 41
Paginas: 65-70
Archivo PDF: 289.07 Kb.


FRAGMENTO

INTRODUCCIÓN

La enfermedad pulmonar obstructiva crónica (EPOC) es una enfermedad caracterizada por limitación irreversible, persistente y progresiva del flujo aéreo, asociada a una respuesta inflamatoria crónica en la vía aérea debido al depósito de partículas nocivas, principalmente relacionadas con el tabaquismo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Barreiro E Gea J. Epigenetics and muscle dysfunction in chronic obstructive pulmonary disease. Translational Research. 2014;165(1):61-73.

  2. Grundy S Plumb J Lea et al. Down Regulation of T Cell Receptor Expression in COPD Pulmonary CD8 Cells. PLoS ONE. 2013;8(8):1-11.

  3. Ezzie ME Crawford M Cho J. et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax. 2012;67(2):122-131.

  4. Christenson S Brandsma CA Campbell JD et al. miR-638 regulates gene expression networks associated with emphysematous lung destruction. Genome Medicine. 2013;5(12):1-13.

  5. Schamberger AC Mise N Meiners S Eickelberg O. Epigenetic mecanisms in COPD: implications for pathogenesis and drug discovery. Expert Opinion Drug Discovery. 2014;9(6):609-628.

  6. Provinciali M Cardelli M Marchegiani F. Inflammation, chronic obstructive pulmonary disease and aging. Current Opinion in Pulmonary Medicine. 2011; 17(1):S3-S10.

  7. Li LJ Gao LB Lv ML et al. Association between SNPs in pre-miRNA and risk of chronic obstructive pulmonary disease. Clinical Biochemistry. 2011;44(10-11): 813-816.

  8. Molina-Pinelo S Pastor MD Suarez R et al. MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. European Respiratory Journal. 2014;43(6): 1740-1749.

  9. Pagdin PL. MicroRNAs in lung diseases. Thorax. 2011;67(2):183-184.

  10. Chavali S Bruhn S Tiemann et al. MicroRNAs act complementarily to regulate disease-related mRNA modules in human diseases. RNA Journal, 2013;19 (11):1552-1562.

  11. Angulo M Lecuona E Iasha Sznajder J. Rol de los microARN en las enfermedades pulmonares. Archivos de Bronconeumologia. 2012;48(9):325-330.

  12. Sessa R Hata A. Role of microRNAs in lung development and pulmonary diseases. Pulmonary Circulation. 2013;3 (2):315-328.

  13. Barreiro E Sznajder JI. Epigenetic regulation of muscle phenotype and adaptation: a potential role in COPD muscle dysfunction. Journal of Applied Physiology. 2013;114(9):1263-1272.

  14. Adcock IM Caramori G Barnes PJ. Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights. Respiration. 2011;81(4):265- 284.

  15. Ogelsby I McElvaney N Greene C. MicroRNAs in inflammatory lung disease - master regulators or target practice? Respiratory Research. 2010;11:1-13.

  16. Donaldson A Natanek SA Lewis A et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax. 2013;68(12):1140- 1149.

  17. Wang M Huang Y Liang Z et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. The Clinical Respiratory Journal. 2014: doi: 10.1111/crj.12194.

  18. Basma H Gunji Y Iwasawa et al. Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells. American Journal of Physiology and Lung Cell Molecular Physiology. 2014;306(6):L552-L565.

  19. Brusselle GG Jaos GF Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015-1026.

  20. Kishore A Borucka J Petrkova J Petrek M. Novel insights into miRNA in Lung and Heart Inflammatory Diseases. Mediators of Inflammation. 2014: doi: 10.1155/2014/259131.

  21. Plank M Maltby S Mattes J Foster P. Targeting translational control as a novel way to treat inflammatory disease: the emerging role of MicroRNAs. Clinical and Experimental Allergy. 2013;43(9):981-999.

  22. Francis SM Davidson MR Tan ME et al. MicroRNA-34c is associated with emphysema severity and modulates SERPINE1 expression. BMC Genomics. 2014;15(88):1-8.

  23. Sato T Liu X Nelson A et al. Reduced miR-146a Increases Prostaglandin E2 in Chronic Obstructive Pulmonary Disease Fibroblasts. American Journal of Respiration and Critical Care Medicine. 2010;182(8):1020-1029.

  24. Hassan T Carroll TP Buckley PG et al. miR-199-5p Silencing Regulates the Unfolded Protein Response in Chronic Obstructive Pulmonary Disease and Alfa1- Antitrypsin Deficiency. American Journal of Respiration and Critical Care Medicine. 2014;189(3):263-273.

  25. Mizuno S Yasuo M Bogaard H Kraskauskas D Natarajan R Voelkel N. Inhibition of histone deacetylase causes emphysema. American Journal of Physiology and Lung Cell Molecular Physiology. 2010;300(3):L402-L413.

  26. Takahashi K Yokota S Tatsumi N Fukami T Yokoi T Nakajima M. Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicology and Applied Pharmacology. 2013;272(1):154-160.

  27. Gross TJ Powers LS Boudreau RL et al. A microRNA-processing defect in smokers' macrophages is linked to SUMOylation of the endonuclease DICER. Journal of Biological Chemistry. 2014; 289(18):12823-12834.

  28. Yang IA Rela V Wright CM et al. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opinion Therapy Targets. 2011;15(4):439-456.

  29. Bowman RV Wright CM Davidson MR Francis SM Yang IA Fong KM. Epigenomic targets for the treatment of respiratory disease. Expert Opinion Therapy Targets. 2009;13(6):625-640.

  30. Mizuno S Bogaard HJ Gomez-Arroyo J et al. MicroRNA-199a-5p Is Associated with Hypoxia-Inducible Factor-1alfa Expression in Lungs From Patients with COPD. Chest. 2012;142(3):663-672.

  31. Yue J Guan J Wang X et al. MicroRNA- 206 is involved in hypoxia-induced pulmonary hypertension through targeting of the HIF-1alfa/Fhl-1 pathway. Laboratory Investigation. 2013;93(7):748- 759.

  32. Akbas F Coskunpinar E Aynaci E Musteri Oltulu Y Yildiz P. Analysis of serum micro-RNAs as potential biomarker in Chronic Obstructive Pulmonary Disease. Experimental Lung Research. 2012;38(6):1-9.

  33. Banerjee A Luettich K. MicroRNAs as potential biomarkers of smoking-related diseases. Biomarkers Medicine. 2012;6 (5):671-684.

  34. Puig-Vilanova E Aguilo R Rodriguez- Fuster A Martinez-Llorens J Gea J Barreiro E. Epigenetic Mechanisms in Respiratory Muscle Dysfunction of Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE. 2014;9(11): e111514. doi: 10.1371/journal.pone.0111514

  35. Donaldson A Natanek SA Lewis A et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax. 2013;68(12):1140- 1149.

  36. Leidinger P Keller A Borries A et al. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer. 2011;74(1):41-47.

  37. Lewis A Riddoch-Contreras J Natanek S et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax. 2012;67(1):26-34.

  38. Novak J Kruzliak P Bienertova-Vasku J Slaby O Novak M. MicroRNA-206: a Promising Theranostic Marker. Theranostics. 2014;4(2):119-133.

  39. Ru Y Kechris K Tabakoff B et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Research. 2014;42(17):1-10.

  40. Pinkerton M Chinchilli V Banta E et al. Differential expression of microRNAs in exhaled breath condensates of patients with asthma, patients with chronic obstructive pulmonary disease, and healthy adults. Journal of Allergy and Clinical Inmunology. 2013;132(1):217- 219.

  41. Perry MP Tsitsiou E Austin PJ et al. Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respiratory Research. 2014;15 (58):1-12.




2020     |     www.medigraphic.com